A5041180287- Vasculitis and related conditions
- Systemic Lupus Erythematosus Research
- Long-Term Effects of COVID-19
- Diabetes Management and Education
- COVID-19 and Mental Health
- Chronic Disease Management Strategies
- Health disparities and outcomes
- Retinal and Optic Conditions
- Atherosclerosis and Cardiovascular Diseases
- Healthcare Systems and Reforms
- Pharmaceutical Practices and Patient Outcomes
- Complement system in diseases
- Mental Health Treatment and Access
- COVID-19 and healthcare impacts
- Healthcare Systems and Technology
- Substance Abuse Treatment and Outcomes
- Renal Diseases and Glomerulopathies
- Chronic Kidney Disease and Diabetes
- Otitis Media and Relapsing Polychondritis
- Healthcare Systems and Public Health
- Healthcare cost, quality, practices
Hospital Universitario Nuestra Señora de Candelaria
2021-2025
Instituto Aragonés de Ciencias de la Salud
2021-2023
Instituto de Investigación Sanitaria Aragón
2021-2022
Tocilizumab (TCZ) has demonstrated potential efficacy in managing large-vessel (LV) vasculitis such as giant-cell arteritis (GCA) and Takayasu (TAK). Despite the shared characteristics between LV-GCA phenotype TAK, there are differences both entities that may affect therapeutic responses to TCZ. We aim assess compare effectiveness safety of TCZ patients with TAK. Multicenter, observational study on 70 57 TAK treated Outcomes were assessed at baseline 1, 3, 6 12 months post-treatment...
To analyze the sociodemographic characteristics and trends in clinical analytical parameters among individuals with chronic kidney disease (CKD) Aragon (Spain), who remain uninfected COVID-19 during first year of pandemic. The secondary objectives were to identify associated comorbidities their evolution throughout pandemic, as well determine cases that got worse possible relationship control main risk factors. CKD is a major public health problem worldwide. Studies encompassing national,...
Objective: To assess the efficacy and safety of tocilizumab (TCZ) in Caucasian patients with refractory Takayasu’s arteritis (TAK) clinical practice. Methods: A multicenter study TAK who received TCZ. The outcome variables were remission, glucocorticoid-sparing effect, improvement imaging techniques, adverse events. comparative between TCZ as monotherapy (TCZ MONO ) combined conventional disease modifying anti-rheumatic drugs (cDMARDs) COMBO was performed. Results: comprised 54 (46 women/8...
The disruption in healthcare attention to people with alcohol dependence, along psychological decompensation as a consequence of lockdown derived from the COVID-19 pandemic could have negative impact on who suffer abuse disorder. Observational real world data pre-post study included 9966 men aged >16 years registered having diagnosis disorder electronic medical records (EMR) Aragon Regional Health Service (Spain). Clinical (Glutamate-oxaloacetate -GOT-, Glutamate pyruvate -GPT-, creatinine,...
Background: Tocilizumab (TCZ) was recently approved for Takayasu Arteritis (TAK) in Japan based on the results of TAKT trial (1). However, data clinical practice Europe and America are scarce (2). Objectives: To assess efficacy safety TCZ TAK Spain. Methods: Observational, open-label multicentre study 53 patients treated with due to refractoriness or adverse events previous therapy. Outcomes variables were improvement features, acute phase reactants glucocorticoid-sparing effect. Results:...
Background In recent years, different tools have been developed to facilitate analysis of social determinants health (SDH) and apply this policy. The possibility generating predictive models outcomes which combine a wide range socioeconomic indicators with problems is an approach that receiving increasing attention. Our objectives are twofold: (1) predict population measured as hospital morbidity, taking primary care (PC) morbidity adjusted for SDH predictors; (2) analyze the geographic...
The disruption in healthcare attention to people with alcohol dependence, along psychological decompensation consequence of lockdown derived from COVID-19 pandemic, could have a negative impact on who suffers abuse disorder. Retrospective observational study 9,966 men aged ˃16 years registered as having diagnosis disorder the electronic medical records (EMR) Aragon Regional Health Service (Spain). Of those were not infected during period (9,576), clinical (Glutamate-oxaloacetate -GOT-,...
Background: Tocilizumab (TCZ) has shown to be effective for large vessel vasculitis including Takayasu arteritis (TAK) (1-3). Most evidence in TAK comes from Asian patients. However, white patients seem have different clinical and prognostic features. Objectives: Our aims were to: a ) assess the efficacy safety of TCZ with refractory TAK, b determine if improvement correlates imaging outcomes, c compare monotherapy (TCZ MONO vs combined conventional immunosuppressive drugs COMBO Methods:...